The Goldman Sachs Group Increases Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Price Target to $55.00

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) had its price objective increased by equities researchers at The Goldman Sachs Group from $45.00 to $55.00 in a report released on Wednesday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. The Goldman Sachs Group’s price target would indicate a potential upside of 47.49% from the stock’s current price.

A number of other research firms have also recently issued reports on KNSA. Jefferies Financial Group boosted their price objective on shares of Kiniksa Pharmaceuticals International from $45.00 to $54.00 and gave the company a “buy” rating in a research report on Tuesday, July 29th. Weiss Ratings restated a “hold (c)” rating on shares of Kiniksa Pharmaceuticals International in a research report on Wednesday, October 8th. Wedbush restated an “outperform” rating and issued a $48.00 price objective (up previously from $44.00) on shares of Kiniksa Pharmaceuticals International in a research report on Tuesday. Zacks Research lowered shares of Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “hold” rating in a research note on Monday, October 6th. Finally, Citigroup lifted their target price on shares of Kiniksa Pharmaceuticals International from $45.00 to $50.00 and gave the company a “buy” rating in a research note on Friday, October 17th. Seven research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $50.29.

Kiniksa Pharmaceuticals International Stock Down 0.2%

Shares of NASDAQ:KNSA opened at $37.29 on Wednesday. The stock has a market cap of $2.76 billion, a PE ratio of 82.87 and a beta of 0.16. The company’s fifty day moving average is $36.85 and its 200 day moving average is $30.95. Kiniksa Pharmaceuticals International has a 52 week low of $17.82 and a 52 week high of $42.05.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last issued its earnings results on Tuesday, November 4th. The company reported $0.23 EPS for the quarter, missing analysts’ consensus estimates of $0.31 by ($0.08). The business had revenue of $180.85 million during the quarter, compared to analysts’ expectations of $166.64 million. Kiniksa Pharmaceuticals International had a return on equity of 7.46% and a net margin of 6.01%.Kiniksa Pharmaceuticals International’s revenue for the quarter was up 61.2% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.18) EPS. Sell-side analysts anticipate that Kiniksa Pharmaceuticals International will post -0.55 EPS for the current year.

Insider Buying and Selling at Kiniksa Pharmaceuticals International

In related news, CEO Sanj K. Patel sold 97,390 shares of the business’s stock in a transaction dated Wednesday, October 22nd. The shares were sold at an average price of $38.83, for a total transaction of $3,781,653.70. Following the sale, the chief executive officer owned 111,794 shares of the company’s stock, valued at $4,340,961.02. The trade was a 46.56% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CAO Michael R. Megna sold 50,490 shares of the business’s stock in a transaction dated Monday, October 20th. The stock was sold at an average price of $38.87, for a total transaction of $1,962,546.30. Following the sale, the chief accounting officer directly owned 27,046 shares in the company, valued at $1,051,278.02. The trade was a 65.12% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 905,398 shares of company stock worth $32,347,674. Insiders own 53.48% of the company’s stock.

Institutional Investors Weigh In On Kiniksa Pharmaceuticals International

Several hedge funds have recently bought and sold shares of KNSA. Wealth Enhancement Advisory Services LLC bought a new position in shares of Kiniksa Pharmaceuticals International in the first quarter worth approximately $301,000. GAMMA Investing LLC lifted its stake in shares of Kiniksa Pharmaceuticals International by 84.8% in the first quarter. GAMMA Investing LLC now owns 1,238 shares of the company’s stock worth $27,000 after buying an additional 568 shares in the last quarter. Deutsche Bank AG lifted its stake in shares of Kiniksa Pharmaceuticals International by 177.1% in the first quarter. Deutsche Bank AG now owns 394,522 shares of the company’s stock worth $8,762,000 after buying an additional 252,125 shares in the last quarter. Victory Capital Management Inc. bought a new position in shares of Kiniksa Pharmaceuticals International in the first quarter worth approximately $1,184,000. Finally, Invesco Ltd. lifted its stake in shares of Kiniksa Pharmaceuticals International by 137.4% in the first quarter. Invesco Ltd. now owns 33,492 shares of the company’s stock worth $744,000 after buying an additional 19,384 shares in the last quarter. Institutional investors own 53.95% of the company’s stock.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.